Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne R Hayman

Showing results (31-40 of 242) with videos related to

Pageof 25
Sort By:
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Mayo Clinic Proceedings|January 7, 2018
Safety Outcomes for Autologous Stem Cell Transplant in Multiple MyelomaMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
Cancer|October 20, 2011
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myelomaShaji K Kumar, Martha Q Lacy, Angela Dispenzieri, et al.
Leukemia & Lymphoma|July 9, 2016
Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myelomaRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Blood|December 8, 2011
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementSumit Madan, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2017
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk CytogeneticsRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Pageof 25

Showing results (31-40 of 242) with videos related to

Sort By:
Pageof 25
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Mayo Clinic Proceedings|January 7, 2018
Safety Outcomes for Autologous Stem Cell Transplant in Multiple MyelomaMorie A Gertz, Francis K Buadi, Suzanne R Hayman, et al.
American Journal of Hematology|June 1, 2010
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndromeTrista Stankowski-Drengler, Morie A Gertz, Jerry A Katzmann, et al.
Cancer|October 20, 2011
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myelomaShaji K Kumar, Martha Q Lacy, Angela Dispenzieri, et al.
Leukemia & Lymphoma|July 9, 2016
Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myelomaRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
European Journal of Haematology|June 8, 2012
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantationJonathan S Bleeker, Morie A Gertz, Patricia A Pellikka, et al.
Blood|December 8, 2011
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvementSumit Madan, Shaji K Kumar, Angela Dispenzieri, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 25, 2017
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk CytogeneticsRajshekhar Chakraborty, Eli Muchtar, Shaji K Kumar, et al.
Pageof 25